Antitumor necrotic factor agent promotes BMP-2-induced ectopic bone formation.

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Orthopedics

Background:

• Etanercept (ETN) is a biologic agent used to treat rheumatoid arthritis by inhibiting tumor necrosis factor (TNF).
• Recombinant human bone morphogenetic protein-2 (rhBMP-2) is known to induce ectopic bone formation.
• Investigating novel applications for ETN in bone regeneration is of significant interest.

Purpose of the Study:

• To evaluate the effect of Etanercept (ETN) on rhBMP-2-induced ectopic bone formation in vivo.
• To determine the optimal dosage and administration route (systemic vs. local) for ETN in enhancing bone formation.
• To assess potential adverse effects of ETN administration in this context.

Main Methods:

• A biodegradable polymer (PLA-DX-PEG) was used as a delivery system for rhBMP-2.
• Polymer discs containing rhBMP-2 were implanted into mice, with ETN administered systemically or locally.
• Radiodensity, bone mineral content, and histomorphological parameters were analyzed after 3 weeks.

Main Results:

• Optimal doses of ETN significantly increased bone mineral content and radiodensity of the ossicles.
• Histomorphology showed increased bone volume, osteoblast numbers, and osteoblast surface.
• A significant decrease in osteoclast numbers and osteoclast surface was observed in ETN-treated groups.

Conclusions:

• Etanercept (ETN) effectively enhances the bone-inducing capacity of rhBMP-2.
• Both systemic and local administration of ETN at optimal doses promote ectopic bone formation.
• The study suggests ETN may be a valuable adjunct in bone regenerative therapies without significant adverse effects.